Zhang Min, Prosser Benjamin L, Bamboye Moradeke A, Gondim Antonio N S, Santos Celio X, Martin Daniel, Ghigo Alessandra, Perino Alessia, Brewer Alison C, Ward Christopher W, Hirsch Emilio, Lederer W Jonathan, Shah Ajay M
King's College London British Heart Foundation Centre of Excellence, London, United Kingdom.
Department of Physiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
J Am Coll Cardiol. 2015 Jul 21;66(3):261-272. doi: 10.1016/j.jacc.2015.05.020.
Renin-angiotensin system activation is a feature of many cardiovascular conditions. Activity of myocardial reduced nicotinamide adenine dinucleotide phosphate oxidase 2 (NADPH oxidase 2 or Nox2) is enhanced by angiotensin II (Ang II) and contributes to increased hypertrophy, fibrosis, and adverse remodeling. Recent studies found that Nox2-mediated reactive oxygen species production modulates physiological cardiomyocyte function.
This study sought to investigate the effects of cardiomyocyte Nox2 on contractile function during increased Ang II activation.
We generated a cardiomyocyte-targeted Nox2-transgenic mouse model and studied the effects of in vivo and ex vivo Ang II stimulation, as well as chronic aortic banding.
Chronic subpressor Ang II infusion induced greater cardiac hypertrophy in transgenic than wild-type mice but unexpectedly enhanced contractile function. Acute Ang II treatment also enhanced contractile function in transgenic hearts in vivo and transgenic cardiomyocytes ex vivo. Ang II-stimulated Nox2 activity increased sarcoplasmic reticulum (SR) Ca(2+) uptake in transgenic mice, increased the Ca(2+) transient and contractile amplitude, and accelerated cardiomyocyte contraction and relaxation. Elevated Nox2 activity increased phospholamban phosphorylation in both hearts and cardiomyocytes, related to inhibition of protein phosphatase 1 activity. In a model of aortic banding-induced chronic pressure overload, heart function was similarly depressed in transgenic and wild-type mice.
We identified a novel mechanism in which Nox2 modulates cardiomyocyte SR Ca(2+) uptake and contractile function through redox-regulated changes in phospholamban phosphorylation. This mechanism can drive increased contractility in the short term in disease states characterized by enhanced renin-angiotensin system activation.
肾素-血管紧张素系统激活是许多心血管疾病的一个特征。血管紧张素II(Ang II)可增强心肌烟酰胺腺嘌呤二核苷酸磷酸氧化酶2(NADPH氧化酶2或Nox2)的活性,并导致心肌肥厚、纤维化及不良重塑加重。最近的研究发现,Nox2介导的活性氧生成可调节心肌细胞的生理功能。
本研究旨在探讨在Ang II激活增强的情况下,心肌细胞Nox2对收缩功能的影响。
我们构建了一种心肌细胞靶向的Nox2转基因小鼠模型,并研究了体内和体外Ang II刺激以及慢性主动脉缩窄的影响。
慢性低剂量Ang II输注在转基因小鼠中比野生型小鼠诱导出更大程度的心脏肥大,但出乎意料的是增强了收缩功能。急性Ang II处理也增强了转基因心脏的体内收缩功能和转基因心肌细胞的体外收缩功能。Ang II刺激的Nox2活性增加了转基因小鼠肌浆网(SR)Ca2+摄取,增加了Ca2+瞬变和收缩幅度,并加速了心肌细胞的收缩和舒张。Nox2活性升高增加了心脏和心肌细胞中受磷蛋白的磷酸化,这与蛋白磷酸酶1活性的抑制有关。在主动脉缩窄诱导的慢性压力超负荷模型中,转基因小鼠和野生型小鼠的心脏功能同样受到抑制。
我们发现了一种新机制,即Nox2通过氧化还原调节受磷蛋白磷酸化的变化来调节心肌细胞SR Ca2+摄取和收缩功能。这种机制可在短期内驱动以肾素-血管紧张素系统激活增强为特征的疾病状态下的收缩力增加。